{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T03:26:12Z","timestamp":1782876372567,"version":"3.54.5"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.neuropharm.2017.07.005","type":"journal-article","created":{"date-parts":[[2017,7,8]],"date-time":"2017-07-08T04:30:21Z","timestamp":1499488221000},"page":"30-38","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Behavioural pharmacology of the \u03b15-GABA A receptor antagonist S44819: Enhancement and remediation of cognitive performance in preclinical models"],"prefix":"10.1016","volume":"125","author":[{"given":"Istv\u00e1n","family":"Gacs\u00e1lyi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krisztina","family":"M\u00f3ricz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e1bor","family":"Gigler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e1nos","family":"Wellmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katalin","family":"Nagy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Istv\u00e1n","family":"Ling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f3zsef","family":"Bark\u00f3czy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f3zsef","family":"Haller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy J.","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e1bor","family":"Sz\u00e9n\u00e1si","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Spedding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferenc A.","family":"Antoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2017.07.005_bib1","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.2174\/156802611795371314","article-title":"GABAA receptor subtype-selective modulators. II. alpha5-selective inverse agonists for cognition enhancement","volume":"11","author":"Atack","year":"2011","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.neuropharm.2017.07.005_bib2","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s00213-008-1357-7","article-title":"RO4938581, a novel cognitive enhancer acting at GABAA alpha5 subunit-containing receptors","volume":"202","author":"Ballard","year":"2009","journal-title":"Psychopharmacol. (Berl.)"},{"key":"10.1016\/j.neuropharm.2017.07.005_bib3","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1038\/npp.2016.49","article-title":"A\u00a0pharmacogenetic 'Restriction-of-Function' approach reveals evidence for anxiolytic-like actions mediated by alpha5-containing GABAA receptors in mice","volume":"41","author":"Behlke","year":"2016","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2017.07.005_bib4","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1038\/nn.4102","article-title":"Regulating anxiety with extrasynaptic inhibition","volume":"18","author":"Botta","year":"2015","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuropharm.2017.07.005_bib5","doi-asserted-by":"crossref","first-page":"3662","DOI":"10.1073\/pnas.0307231101","article-title":"Tonic inhibition in mouse hippocampal CA1 pyramidal neurons is mediated by alpha5 subunit-containing gamma-aminobutyric acid type A receptors","volume":"101","author":"Caraiscos","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2017.07.005_bib6","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1021\/jm020582q","article-title":"Identification of a novel, selective GABA(A) alpha5 receptor inverse agonist which enhances cognition","volume":"46","author":"Chambers","year":"2003","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.neuropharm.2017.07.005_bib7","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/nature09559","article-title":"Encoding of conditioned fear in central amygdala inhibitory circuits","volume":"468","author":"Ciocchi","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2017.07.005_bib8","doi-asserted-by":"crossref","first-page":"12312","DOI":"10.1523\/JNEUROSCI.1689-16.2016","article-title":"Effects of the selective alpha5-GABAAR Antagonist S44819 on excitability in the human brain: a TMS-EMG and TMS-EEG Phase I study","volume":"36","author":"Darmani","year":"2016","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2017.07.005_bib9","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/0166-4328(93)90102-V","article-title":"Fear-potentiated startle: a neural and pharmacological analysis","volume":"58","author":"Davis","year":"1993","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2017.07.005_bib10","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1017\/S1092852900009871","article-title":"Development of subtype selective GABAA modulators","volume":"10","author":"Dawson","year":"2005","journal-title":"CNS Spectr."},{"key":"10.1016\/j.neuropharm.2017.07.005_bib11","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1124\/jpet.105.092320","article-title":"An inverse agonist selective for alpha5 subunit-containing GABAA receptors enhances cognition","volume":"316","author":"Dawson","year":"2006","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2017.07.005_bib12","series-title":"Selective Targeting of Extra-synaptic \u03b15-GABAA Receptors Receptors by a New Therapeutic Agent S44819 (Egis-13529)","author":"Etherington","year":"2017"},{"key":"10.1016\/j.neuropharm.2017.07.005_bib13","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0014-2999(03)01273-1","article-title":"A\u00a0review of 25 years of the social interaction test","volume":"463","author":"File","year":"2003","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.07.005_bib14","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1038\/npp.2015.112","article-title":"Rapid antidepressant action and restoration of excitatory synaptic strength after chronic stress by negative modulators of alpha5-containing GABAA receptors","volume":"40","author":"Fischell","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2017.07.005_bib15","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.neuropharm.2012.07.017","article-title":"Egis-11150: a candidate antipsychotic compound with procognitive efficacy in rodents","volume":"64","author":"Gacs\u00e1lyi","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2017.07.005_bib16","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1523\/JNEUROSCI.4751-07.2008","article-title":"Which GABA(A) receptor subunits are necessary for tonic inhibition in the hippocampus?","volume":"28","author":"Glykys","year":"2008","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2017.07.005_bib17","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.bbr.2007.06.012","article-title":"Atypical antipsychotics attenuate a sub-chronic PCP-induced cognitive deficit in the novel object recognition task in the rat","volume":"184","author":"Grayson","year":"2007","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2017.07.005_bib18","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1126\/science.1149381","article-title":"Neuronal diversity and temporal dynamics: the unity of hippocampal circuit operations","volume":"321","author":"Klausberger","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2017.07.005_bib19","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.brainresbull.2005.11.015","article-title":"Pharmacological evaluation of the stress-induced social avoidance model of anxiety","volume":"69","author":"Leveleki","year":"2006","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.neuropharm.2017.07.005_bib20","series-title":"Dihydro-oxazolobenzodiazepinone Compounds, a Process for Their Preparation and Pharmaceutical Compositions Containing Them, US 2012\/0232065 A1","author":"Ling","year":"2012"},{"key":"10.1016\/j.neuropharm.2017.07.005_bib21","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.ejphar.2015.07.005","article-title":"A\u00a0novel GABA(A) alpha 5 receptor inhibitor with therapeutic potential","volume":"764","author":"Ling","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.07.005_bib22","doi-asserted-by":"crossref","first-page":"5269","DOI":"10.1523\/JNEUROSCI.4209-09.2010","article-title":"Alpha5GABAA receptor activity sets the threshold for long-term potentiation and constrains hippocampus-dependent memory","volume":"30","author":"Martin","year":"2010","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2017.07.005_bib23","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/sj.mp.4001939","article-title":"Mechanisms of fear extinction","volume":"12","author":"Myers","year":"2006","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2017.07.005_bib24","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/nature13294","article-title":"Engineering a memory with LTD and LTP","volume":"511","author":"Nabavi","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2017.07.005_bib25","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0306-4522(00)00442-5","article-title":"GABA(A) receptors: immunocytochemical distribution of 13 subunits in the adult rat brain","volume":"101","author":"Pirker","year":"2000","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2017.07.005_bib26","doi-asserted-by":"crossref","first-page":"146","DOI":"10.3389\/fpsyt.2010.00146","article-title":"Translational aspects of the novel object recognition task in rats abstinent following sub-chronic treatment with phencyclidine (PCP): effects of modafinil and relevance to cognitive deficits in schizophrenia","volume":"1","author":"Redrobe","year":"2010","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.neuropharm.2017.07.005_bib27","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s00213-011-2593-9","article-title":"Negative modulation of GABAA alpha5 receptors by RO4938581 attenuates discrete sub-chronic and early postnatal phencyclidine (PCP)-induced cognitive deficits in rats","volume":"221","author":"Redrobe","year":"2012","journal-title":"Psychopharmacol. (Berl.)"},{"key":"10.1016\/j.neuropharm.2017.07.005_bib28","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1146\/annurev-pharmtox-011613-135947","article-title":"GABAA receptor subtypes: therapeutic potential in Down syndrome, affective disorders, schizophrenia, and autism","volume":"54","author":"Rudolph","year":"2014","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.neuropharm.2017.07.005_bib29","doi-asserted-by":"crossref","first-page":"4885","DOI":"10.1113\/jphysiol.2011.215244","article-title":"Age-dependent remodelling of inhibitory synapses onto hippocampal CA1 oriens-lacunosum moleculare interneurons","volume":"589","author":"Salesse","year":"2011","journal-title":"J.\u00a0Physiol."},{"key":"10.1016\/j.neuropharm.2017.07.005_bib30","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/0028-3908(93)90066-C","article-title":"Kindling to the benzodiazepine receptor inverse agonist, FG 7142: evidence for involvement of NMDA, but not non-NMDA, glutamatergic receptors","volume":"32","author":"Stephens","year":"1993","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2017.07.005_bib31","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.brainresbull.2006.10.006","article-title":"Mechanisms underlying the long-term behavioral effects of traumatic experience in rats: the role of serotonin\/noradrenaline balance and NMDA receptors","volume":"71","author":"Sziray","year":"2007","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.neuropharm.2017.07.005_bib32","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1523\/JNEUROSCI.17-02-00625.1997","article-title":"Bicuculline and gabazine are allosteric inhibitors of channel opening of the GABAA receptor","volume":"17","author":"Ueno","year":"1997","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2017.07.005_bib33","doi-asserted-by":"crossref","first-page":"9375","DOI":"10.1523\/JNEUROSCI.17-23-09375.1997","article-title":"Double dissociation between the involvement of the bed nucleus of the stria terminalis and the central nucleus of the amygdala in startle increases produced by conditioned versus unconditioned fear","volume":"17","author":"Walker","year":"1997","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2017.07.005_bib34","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/BF00965107","article-title":"Glutamate, GABA, and CNS disease: a review","volume":"8","author":"Walker","year":"1983","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.neuropharm.2017.07.005_bib35","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1523\/JNEUROSCI.12-03-01040.1992","article-title":"The distribution of 13 GABAA receptor subunit mRNAs in the rat brain. I. Telencephalon, diencephalon, mesencephalon","volume":"12","author":"Wisden","year":"1992","journal-title":"J.\u00a0Neurosci."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002839081730312X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002839081730312X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,28]],"date-time":"2019-09-28T23:37:33Z","timestamp":1569713853000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002839081730312X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":35,"alternative-id":["S002839081730312X"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2017.07.005","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Behavioural pharmacology of the \u03b15-GABAA receptor antagonist S44819: Enhancement and remediation of cognitive performance in preclinical models","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2017.07.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}